Jeffrey Glenn, of medicine and of microbiology and immunology, has spent years developing new ways to disrupt normal cellular processes in viruses. This work has led to drugs that can shrink and prevent the spread of tumors in mice. (Image credit: Courtesy of Stanford Medicine)
Jeffrey Glenn, of medicine and of microbiology and immunology, has spent years developing new ways to disrupt normal cellular processes in viruses. This work has led to drugs that can shrink and prevent the spread of tumors in mice. (Image credit: Courtesy of Stanford Medicine) An effort to thwart viral diseases like hepatitis or the common cold led to a new collaboration and a novel class of cancer drugs that appears effective in mice. Stanford virologist Jeffrey Glenn did not set out to tackle cancer. For years, he and his lab have worked to develop new ways of battling viruses like the ones that cause hepatitis delta and the common cold - but the lessons they've learned fighting viruses has led to a new kind of drug that has been effective at treating cancer in mice. The underlying idea, Glenn said, is to disrupt otherwise normal cellular processes that both viruses and some cancer cells rely on to grow and spread. Now, tests in mice show that drugs based on that idea can shrink tumors and prevent their spread.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
